fluconazole and HIV
fluconazole has been researched along with HIV in 20 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines." | 5.69 | How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? ( Boulware, DR; Harrison, TS; Hosseinipour, MC; Jarvis, JN; Lawrence, DS; Lortholary, O; Meintjes, G; Mosepele, M; Mwandumba, HC, 2023) |
| "Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia." | 5.20 | Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. ( Achan, B; Akampurira, A; Alhadab, AA; Boulware, DR; Hullsiek, KH; McDonald, TR; Meya, DB; Nielsen, K; Okagaki, LH; Rhein, JR; Smith, KD, 2015) |
| "HIV-uninfected CM patients who received high-dose fluconazole (800 mg/d) for initial therapy in Huashan Hospital were included in this retrospective study from January 2013 to December 2018." | 4.31 | Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not? ( Cheng, JH; Jiang, YK; Luo, Y; Wang, X; Zhao, HZ; Zhou, LH; Zhu, LP; Zhu, RS, 2023) |
| "The objective of this study was to determine the pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus (HIV) infection." | 3.69 | Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. ( Brady, MT; Nahata, MC, 1995) |
| "When mycoses are diagnosed early and treated with the appropriate drugs, favorable therapeutic outcomes can be achieved." | 1.72 | Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report. ( de Lima-Neto, RG; de Melo, HRL; de Sousa, BR; Neves, RP; Silva, GM; Torres, KB, 2022) |
| "Fluconazole 1200mg was prescribed to 29 (63%) patients." | 1.46 | [Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast]. ( Doumbia, A; Eholié, SP; Ehui, E; Ello, NF; Kassi, FK; Kassi, NA; Keita, M; Kouakou, GA; Mossou, C; Tanon, A, 2017) |
| "Cryptococcosis is rare among children, only occurring in about 1% of children with HIV." | 1.38 | Disseminated cryptococcosis in an HIV-positive boy. ( Friedman, D; Kongthavonsakul, K; Oberdorfer, P, 2012) |
Research
Studies (20)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Zhao, HZ | 1 |
| Cheng, JH | 1 |
| Zhou, LH | 1 |
| Luo, Y | 1 |
| Zhu, RS | 1 |
| Jiang, YK | 1 |
| Wang, X | 1 |
| Zhu, LP | 1 |
| Harrison, TS | 1 |
| Lawrence, DS | 1 |
| Mwandumba, HC | 1 |
| Boulware, DR | 2 |
| Hosseinipour, MC | 1 |
| Lortholary, O | 1 |
| Meintjes, G | 1 |
| Mosepele, M | 1 |
| Jarvis, JN | 1 |
| Silva, GM | 1 |
| de Sousa, BR | 1 |
| Torres, KB | 1 |
| Neves, RP | 1 |
| de Melo, HRL | 1 |
| de Lima-Neto, RG | 1 |
| Samukawa, S | 3 |
| Yoshimi, R | 3 |
| Kojitani, N | 3 |
| Uzawa, Y | 3 |
| Takase-Minegishi, K | 3 |
| Kirino, Y | 3 |
| Soejima, Y | 3 |
| Kato, H | 3 |
| Nakajima, H | 3 |
| Monzani, V | 1 |
| Córdoba, S | 1 |
| Vivot, M | 1 |
| Arias, B | 1 |
| Vivot, W | 1 |
| Szusz, W | 1 |
| Castellaro, P | 1 |
| Appendino, A | 1 |
| Taverna, CG | 1 |
| Otto, SBJ | 1 |
| George, PE | 1 |
| Mercedes, R | 1 |
| Nabukeera-Barungi, N | 1 |
| Warrell, CE | 1 |
| Macrae, C | 1 |
| McLean, ARD | 1 |
| Wilkins, E | 1 |
| Ashley, EA | 1 |
| Smithuis, F | 1 |
| Tun, NN | 1 |
| Brilhante, RSN | 1 |
| Guedes, GMM | 1 |
| Silva, MLQD | 1 |
| Castelo-Branco, DSCM | 1 |
| Cordeiro, RA | 1 |
| Sidrim, JJC | 1 |
| Rocha, MFG | 1 |
| Yang, JJ | 1 |
| Huang, CH | 1 |
| Liu, CE | 1 |
| Tang, HJ | 1 |
| Yang, CJ | 1 |
| Lee, YC | 1 |
| Lee, KY | 1 |
| Tsai, MS | 1 |
| Lin, SW | 1 |
| Chen, YH | 1 |
| Lu, PL | 1 |
| Hung, CC | 1 |
| Smith, KD | 1 |
| Achan, B | 1 |
| Hullsiek, KH | 1 |
| McDonald, TR | 1 |
| Okagaki, LH | 1 |
| Alhadab, AA | 1 |
| Akampurira, A | 1 |
| Rhein, JR | 1 |
| Meya, DB | 1 |
| Nielsen, K | 1 |
| Das, PP | 1 |
| Saikia, L | 1 |
| Nath, R | 1 |
| Phukan, SK | 1 |
| Kouakou, GA | 1 |
| Ello, NF | 1 |
| Kassi, NA | 1 |
| Keita, M | 1 |
| Doumbia, A | 1 |
| Mossou, C | 1 |
| Kassi, FK | 1 |
| Tanon, A | 1 |
| Ehui, E | 1 |
| Eholié, SP | 1 |
| Friedman, D | 1 |
| Kongthavonsakul, K | 1 |
| Oberdorfer, P | 1 |
| Lilly, EA | 1 |
| Shetty, KV | 1 |
| Leigh, JE | 1 |
| Cheeks, C | 1 |
| Fidel, PL | 1 |
| Legout, L | 1 |
| Assal, M | 1 |
| Rohner, P | 1 |
| Lew, D | 1 |
| Bernard, L | 1 |
| Hoffmeyer, P | 1 |
| Nahata, MC | 1 |
| Brady, MT | 1 |
| Gripshover, BM | 1 |
| Valdez, H | 1 |
| Salata, RA | 1 |
| Lederman, MM | 1 |
| Powderly, WG | 1 |
| Ford, BJ | 1 |
| Barr, D | 1 |
| Smart, T | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis[NCT01802385] | Phase 3 | 460 participants (Actual) | Interventional | 2015-03-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Center for Epidemiologic Studies in Depression (CES-D) Scale
Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 16.6 |
| Sertraline 400mg | 13.2 |
Count of Participants With Cerebrospinal Fluid Sterility
Number of participants with sterile cerebrospinal fluid at 2 weeks (NCT01802385)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 90 |
| Sertraline 400mg | 101 |
Event Free Survival
Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse. (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 116 |
| Sertraline 400mg | 103 |
Number of Participants Experiencing IRIS OR Relapse
Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Sertraline 400mg | 5 |
Quantitative Neurocognitive Performance Score (QNPZ-8)
Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score (Mean) |
|---|---|
| Placebo | -1.4 |
| Sertraline 400mg | -1.3 |
Safety (Occurence of Adverse Events)
Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions (NCT01802385)
Timeframe: 18 weeks
| Intervention | events (Number) |
|---|---|
| Placebo | 121 |
| Sertraline 400mg | 141 |
Survival
18-week survival. The comparison will be between sertraline 400mg group and placebo (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 125 |
| Sertraline 400mg | 109 |
Fungal Clearance as Determined by Early Fungicidal Activity of CDF
To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone. (NCT01802385)
Timeframe: 14 days
| Intervention | -log10 CFU/ml/day (Mean) | |
|---|---|---|
| General Linear Regression | Mixed-Effects Regression | |
| Placebo | 0.47 | 0.33 |
| Sertraline 400mg | .43 | .33 |
Reviews
1 review available for fluconazole and HIV
| Article | Year |
|---|---|
Current approach to the acute management of cryptococcal infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp | 2000 |
Trials
2 trials available for fluconazole and HIV
| Article | Year |
|---|---|
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
Topics: Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coinfection; Cr | 2015 |
Other Studies
17 other studies available for fluconazole and HIV
| Article | Year |
|---|---|
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report.
Topics: Adult; Antifungal Agents; Candidiasis; Esophagitis; Fluconazole; HIV; Humans; Male; Mycoses; Pericar | 2022 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R | 2020 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal | 2020 |
Ambulatory induction phase treatment of cryptococcal meningitis in HIV integrated primary care clinics, Yangon, Myanmar.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Inf | 2021 |
A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
Topics: Amphotericin B; Antifungal Agents; Brazil; Caspofungin; Echinocandins; Fluconazole; Histoplasma; His | 2018 |
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Anti-Infective Agents; Arylamine N-Acetyltransferas | 2014 |
Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Candida; Candidiasis; Child; Child, | 2016 |
[Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast].
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cote d'Ivoire; Dose-Response Relati | 2017 |
Disseminated cryptococcosis in an HIV-positive boy.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Child; Cr | 2012 |
Oral epithelial cell antifungal activity: approaches to evaluate a broad range of clinical conditions.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral | 2005 |
Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient.
Topics: Candida; Candidiasis; Caspofungin; Drug Resistance, Microbial; Echinocandins; Fluconazole; HIV; HIV | 2006 |
Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection.
Topics: Administration, Oral; Adolescent; Child; Female; Fluconazole; HIV; Humans; Male; Pharmacokinetics; T | 1995 |
Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Candidiasis, Oral; | 1998 |
AIDS and Africa.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Africa; AIDS Vaccines; Anti-HIV Agents; Antif | 2000 |
Candidiasis at ICAAC.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antifungal Agents; Biological Availabil | 1995 |